Zosano Pharma Corporation operates as a clinical-stage biopharmaceutical firm dedicated to supplying medicines and other biologically active compounds to patients experiencing migraine episodes. Its innovative transdermal microneedle system serves as the vehicle for this delivery. The company's flagship product, Qtrypta (M207), is a unique formulation of zolmitriptan intended for the immediate management of acute migraines. Zosano Pharma was founded in 2006 and maintains its headquarters in Fremont, California. Notably, on June 1, 2022, the company sought voluntary reorganization protection by filing for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.
| Symbol | ZSANQ |
|---|---|
| Exchange | OTC |
| Sector | Healthcare |
| Industry | Biotechnology |
| CEO | Steven Lo |
| Employees | 40 |
| Headquarters | Fremont, CA, US |
| Website | www.zosanopharma.com |